Pages that link to "Q33995866"
Jump to navigation
Jump to search
The following pages link to Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells (Q33995866):
Displaying 40 items.
- Promises and paradoxes of regulatory T cells in inflammatory bowel disease (Q26777557) (← links)
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (Q26785746) (← links)
- Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis (Q33607108) (← links)
- Ipilimumab and its toxicities: a multidisciplinary approach (Q33777476) (← links)
- Therapy for metastatic melanoma: the past, present, and future. (Q34183225) (← links)
- T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics (Q34577158) (← links)
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (Q35912366) (← links)
- Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis (Q37308199) (← links)
- Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities (Q37312417) (← links)
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis (Q37714359) (← links)
- Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade (Q37809150) (← links)
- Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management (Q38166382) (← links)
- Ipilimumab-induced toxicities and the gastroenterologist. (Q38340321) (← links)
- Systematic review: colitis associated with anti-CTLA-4 therapy. (Q38529051) (← links)
- From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease (Q38619050) (← links)
- Ipilimumab in melanoma (Q38893697) (← links)
- Infliximab for ipilimumab-induced colitis: A series of 13 patients (Q39040949) (← links)
- Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma (Q39449408) (← links)
- Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. (Q40959994) (← links)
- Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis (Q41826015) (← links)
- Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab (Q43065896) (← links)
- Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Q45026631) (← links)
- Immune checkpoint inhibitor colitis: the flip side of the wonder drugs (Q47397659) (← links)
- Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. (Q48369113) (← links)
- Histopathological and Immunophenotypic Features of Ipilimumab-Associated Colitis Compared to Ulcerative Colitis. (Q49719593) (← links)
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q50205173) (← links)
- Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient (Q50653513) (← links)
- Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm (Q50719439) (← links)
- [The pathology of adverse events with immune checkpoint inhibitors]. (Q52879625) (← links)
- Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. (Q53723979) (← links)
- Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. (Q55284597) (← links)
- Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? (Q56897964) (← links)
- Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? (Q64230260) (← links)
- Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab (Q64254899) (← links)
- Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities (Q90291102) (← links)
- Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings (Q90319842) (← links)
- Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors (Q91801532) (← links)
- Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor (Q92060088) (← links)
- Tipping the balance: inhibitory checkpoints in intestinal homeostasis (Q93377252) (← links)
- British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis (Q96585230) (← links)